The long-term efficacy of eltrombopag in children with immune thrombocytopenia
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05857-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Li- Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kunming Children's Hospital, No.288 Qian Xin Road, Kunming, 650228, China. Hauptthemen laut MEDLINE: Pyrazoles, Hydrazines, Benzoates, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Yunnan Province's "High-level Talent Training Support Program - Specialization for Renowned Doctors", Kunming health science and technology personnel training project (2020-SW-32), The 17th batch of training plan for young and middle-aged academic and technical….
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Immune thrombocytopenia (ITP) is the most common autoimmune disorder characterized by decreased platelet counts and impaired platelet production. Eltrombopag has been demonstrated to be safe and effective for children with ITP. It is reported eltrombopag can achieve a sustained response off treatment. However, data on its overall efficacy and safety profile are scarce in children. This study aimed to investigate the long-term efficacy of eltrombopag in children with ITP. Treatment overall response (OR), complete response (CR), response (R), durable response (DR), no response (NR), treatment free remission (TFR), and relapse rate, were assessed in 103 children with ITP during eltrombopag therapy. The OR rate, CR rate, R rate, DR rate, NR rate, TFR rate, and relapse rate were 67.0%, 55.3%, 11.7%, 56.3%, 33.0%, 60%, 36.2%, respectively. Importantly, we discovered that newly diagnosed ITP patients showed a higher DR rate, TFR rate and lower relapse rate compared to persistent and chronic ITP patients. Furthermore, the CR rate, DR rate, and TFR rate of 5 patients under six months were 100%. None of them suffered relapse. The most common adverse event (AEs) was hepatotoxicity (7.77%). Our study highlighted the critical role of eltrombopag as the second-line treatment in children with ITP who were intolerant to first-line therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Kunming Children's Hospital, No.288 Qian Xin Road, Kunming, 650228, China.
- Medical Faculty, Kunming University of Science and Technology, No.727 Jingming South Road, Kunming, 650500, China. xianwen-zhang0717@163.com.
- Department of Hematology, Kunming Children's Hospital, No.288 Qian Xin Road, Kunming, 650228, China. htl99-2@163.com.
Förderung
- Yunnan Province's "High-level Talent Training Support Program - Specialization for Renowned Doctors"
- Kunming health science and technology personnel training project (2020-SW-32), The 17th batch of training plan for young and middle-aged academic and technical…
Zitieren
APA
Yang, L., Sang, B. H., Yang, C. H., Xiao, Z. G., Fang, C. L., Lv, Y., Li, N., Yang, Q., Chai, S. M., Tian, X., Zhang, X. W., & Huang, T. L. (2024). The long-term efficacy of eltrombopag in children with immune thrombocytopenia. Annals of Hematology. https://doi.org/10.1007/s00277-024-05857-y
Vancouver
Yang L, Sang BH, Yang CH, Xiao ZG, Fang CL, Lv Y, et al. The long-term efficacy of eltrombopag in children with immune thrombocytopenia. Annals of Hematology. 2024. doi:10.1007/s00277-024-05857-y
BibTeX
@article{Yang2024,
author = {Yang, Li- and Sang, Bao-Hua and Yang, Chun-Hui and Xiao, Zu-Gang and Fang, Chun-Lian and Lv, Yu and Li, Na and Yang, Qing and Chai, Shu-Min and Tian, Xin and Zhang, Xian-Wen and Huang, Ti-Long},
title = {The long-term efficacy of eltrombopag in children with immune thrombocytopenia},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05857-y}
}
EUVIMED